Delving into the Latest Updates on Pozdeutinurad with Synapse

This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.

Start Date03 Dec 2025

Sponsor / Collaborator

Arthrosi Therapeutics, Inc.

NCT06846515

/ Active, not recruitingPhase 3

A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months

Start Date11 Mar 2025

Sponsor / Collaborator

Arthrosi Therapeutics, Inc.

NCT06439602

/ Active, not recruitingPhase 3

A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months

Start Date26 Jun 2024

Sponsor / Collaborator

Arthrosi Therapeutics, Inc.

100 Clinical Results associated with Pozdeutinurad

Login to view more data

100 Translational Medicine associated with Pozdeutinurad

Login to view more data

100 Patents (Medical) associated with Pozdeutinurad

Login to view more data

1

Literatures (Medical) associated with Pozdeutinurad

01 Sep 2025·Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Comprehensive management of tophaceous wound

Review

Author: Lu, Xinyi ; Liu, Yingkai ; He, Guoyu ; Lu, Shuliang

Tophaceous wound represent a severe complication of end-stage gout, characterized by the deposition of monosodium urate (MSU) crystals leading to localized tissue ischemia, chronic inflammation, and non-healing ulcers. The pathological mechanism involves the formation of MSU crystals under persistent hyperuricemia, inflammatory encapsulation, and mechanical compression of the vascular system due to tophus enlarge-ment, ultimately resulting in chronic non-healing ulcers. This article consolidates current evidence to outline an integrated management strategy for such wounds, combining systemic metabolic control with localized interventions. Effective treatment depends on maintaining serum uric acid levels below 300 μmol/L through urate-lowering agents, including conventional drugs and novel urate transporter 1 inhibitors such as AR882, complemented by anti-inflammatory medications such as nonsteroidal anti-inflammatory drugs and glucocorticoids to alleviate pain and reduce inflammation. Topical agents and advanced dressings are utilized to support healing and manage exudate. Debridement, which encompasses sharp, ultrasonic, and micro-techniques, is essential for removing necrotic tissue and MSU deposits, with efficacy assessed via local uric acid monitoring. Surgical reconstructions, including skin flap grafting and tendon or ligament reconstruction, are indicated for significant tissue loss or functional impairment. Long-term management emphasizes continuous metabolic control, personalized rehabilitation, and lifestyle modification. The comprehensive treatment of tophaceous wounds requires multidisciplinary collaboration to balance local repair and systemic regulation for improved prognosis. Future research directions include gene therapy to regulate purine metabolism and artificial intelligence-assisted personalized treatment plans, to achieve precision medicine for tophaceous wounds.

40

News (Medical) associated with Pozdeutinurad

18 Feb 2026

·www.prnewswire.com

Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030

STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today hosts its Capital Markets Day, where senior management will provide an update on the company's strategy and outline its new mid-term outlook, aiming to achieve SEK 55bn revenue by 2030, while building a resilient platform for sustained growth beyond 2030. Sobi aims to have an adjusted EBITA margin in the upper 30s percentage of revenue by 2030. Sobi has delivered strong and profitable growth in recent years, transforming and diversifying its portfolio and positioning the company to deliver on six major launches. Additionally, Sobi is advancing priority development programs enabling longer term growth and continuing its international expansion. "Sobi today is a stronger, more global and more scientifically driven company," says Guido Oelkers, CEO of Sobi. "We have delivered on our commitments, built a diversified, robust foundation for future growth, and are entering the next phase of expansion with multiple launches and compelling opportunities to unlock growth well beyond 2030." Highlights of the Capital Markets Day Sobi shares its ambition to reach SEK 55bn in revenues by 2030, effectively doubling the company revenue driven by six major launches, continued strong performance of strategic products, and international expansion. Sobi outlines major launches either ongoing or in preparation, expected to drive the majority of growth to 2030, including Altuvoct®, Gamifant®, Aspaveli®, Tryngolza®, NASP, and pozdeutinurad, across haematology, immunology, and specialty care. Deep dives demonstrate Sobi's scientific leadership in: Uncontrolled and progressive gout and two potentially transformative treatment innovations in an area of high unmet patient needs. Severe hypertriglyceridemia, where acute pancreatitis is a major risk and a severe medical emergency, and ApoC-III inhibition with olezarsen has shown significant and meaningful reductions in acute pancreatitis risk. Precision medicine in sepsis: In biomarker-selected patients with interferon gamma-driven sepsis (the proof-of-concept EMBRACE study), Sobi will share topline data for empalumab demonstrating improvement in SOFA-based organ function (achieving primary endpoint at end of treatment in 60% patients receiving high dose emapalumab vs 40% in the standard of care plus placebo arm). High dose emapalumab additionally showed a 12-percentage point absolute mortality reduction after 28-days (40% mortality in the high dose emapalumab arm vs 52% in the standard of care plus placebo arm). Additional information provided New peak sales expectations for the following products: Haemophilia A franchise (Altuvoct and Elocta) greater than SEK 10bn, Aspaveli between SEK 7-10bn, Gamifant in HLH between SEK 5-7bn, NASP between SEK 4-6bn, Tryngolza greater than SEK 10bn, pozdeutinurad greater than SEK 10bn and Gamifant in IDS greater than SEK 10bn. R&D expenses to remain between 11-14 per cent of sales on a given year between now and 2030. Agenda in brief The Capital Markets Day includes presentations from Sobi's executive leadership on strategy, pipeline and innovation, commercial opportunities and financial outlook as well as disease deep dives with experts and leaders in their respective fields, and a concluding Q&A session. Pre-registration for online attendance: click here A recording of the presentations and supporting materials will be made available on . Sobi Sobi® is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2025 revenue amounted to SEK 28 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CET on 18 February 2026. Gerard Tobin Head of Investor Relations This information was brought to you by Cision The following files are available for download: SOURCE Swedish Orphan Biovitrum AB 21% more press release views with Request a Demo

Clinical Result

09 Feb 2026

·www.prnewswire.com

Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout

STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) Sobi® (STO: SOBI) and Arthrosi Therapeutics, Inc. (Arthrosi) announced today the completion of the acquisition of Arthrosi by Sobi. Upon completion of the transaction, Sobi has acquired all outstanding shares of Arthrosi's common stock and common stock equivalents. Arthrosi Therapeutics is a private late-stage biotechnology company focused on developing a next-generation treatment for gout. The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently being evaluated in two fully recruited global Phase 3 clinical studies for the potential management of progressive and tophaceous gout and expected to read out in 2026. Pozdeutinurad complements Sobi's pipeline by adding a potentially best-in-class URAT1 inhibitor for patients sub-optimally treated with first-line therapies. Today's announcement reflects Sobi's commitment to advancing treatment options for people living with gout. About Pozdeutinurad Pozdeutinurad (AR882) is an investigational URAT1 inhibitor being developed for the treatment of progressive and tophaceous gout and has completed Phase 2 studies that demonstrated compelling efficacy with a sustained reduction of serum uric acid, dissolution of tophi and a well-tolerated safety profile. It is currently being evaluated in two Phase 3 studies, REDUCE 1 and REDUCE 2, two twelve-month, randomized, double-blind, placebo-controlled studies to assess pozdeutinurad's ability to reduce sUA in patients with progressive and tophaceous gout. Both Phase 3 studies are now fully enrolled, and the pivotal data is expected in 2026. About Arthrosi Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing pozdeutinurad, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with progressive gout. The rights to pozdeutinurad in Greater China are held by ApicHope. About Gout Gout is the most common form of inflammatory arthritis. Gout is caused by high levels of uric acid in the body that accumulate around the joints and other tissues and can result in flares that cause intense pain. When gout is left untreated, it can become a progressive disease with serious consequences. Over time, frequent flares and persistent uric acid buildup can lead to chronic joint damage, reduced mobility, and the formation of tophi (hard deposits under the skin). While many patients with chronic gout are treated in first line with urate lowering therapy some are sub-optimally treated or do not respond to first line therapies and the disease progresses. In later lines, uncontrolled gout is associated with a higher risk of comorbidities such as kidney disease and cardiovascular complications, making early diagnosis and effective management critical. Despite available treatments, many patients struggle to achieve target uric acid levels, underscoring the need for innovative therapies to prevent long-term disability and improve quality of life. Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. Gerard Tobin Head of Investor Relations This information was brought to you by Cision The following files are available for download: 21% more press release views with Request a Demo

Phase 2Phase 3Acquisition

15 Dec 2025

·www.fiercebiotech.com

Sobi pays $950M upfront to snap up phase 3 gout specialist Arthrosi Therapeutics

Under a new deal, Sobi gets its hands on Arthrosi Therapeutics’ pozdeutinurad, a next-gen, once-daily oral URAT1 inhibitor.\n Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a potential value of $1.5 billion from Swedish biopharma Sobi. Under the deal, San Diego-based Arthrosi will secure $950 million upfront as well as a contingent consideration of up to $550 million. For its part, Sobi gets its hands on Arthrosi’s pozdeutinurad, a next-gen, once-daily oral URAT1 inhibitor.This med is being assessed in several phase 3 tests for progressive and tophaceous gout, with initial readouts slated for next year.“The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset,” Guido Oelkers, president and CEO of Sobi, said in a statement.“Pozdeutinurad has the potential to become the therapy of choice for patients who have progressive gout with persistent and unresolved symptoms despite first-line therapy,” the CEO added.Gout is a type of arthritis that causes sudden, severe joint pain. Common drug treatment includes simple pain relief, but pharma has been working on potential curative treatments for decades, though with mixed results.Arthrosi’s leading drug candidate is an inhibitor of URAT1, a transporter that has been a target for gout drugs going back to the approval of probenecid in 1951. Probenecid and other early gout drugs hit multiple targets but also caused a range of side effects. Seeking to avoid the adverse events, developers of subsequent waves of gout drugs tried to create more potent and specific URAT1 inhibitors.AstraZeneca acquired a URAT1 inhibitor in its $1.3 billion takeover of Ardea Biosciences in 2012 and won FDA approval for the drug in 2015. By 2020, the product, Zurampic, had, however, landed on the scrap heap.The commercial struggles of Zurampic, which carried a boxed warning, didn\'t deter others from trying to launch URAT1 inhibitors.A team behind Zurampic has reformed at Crystalys Therapeutics to advance dotinurad, a URAT1 inhibitor that is approved in Asian markets including Japan. And China’s Atom Therapeutic recently reported a phase 2b/3 win for its own URAT1 inhibitor, lingdolinurad.

Drug ApprovalPhase 3AcquisitionIPO

100 Deals associated with Pozdeutinurad

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthritis, Gouty	Phase 3	United States	Arthrosi Therapeutics, Inc.	26 Jun 2024
Arthritis, Gouty	Phase 3	Australia	Arthrosi Therapeutics, Inc.	26 Jun 2024
Arthritis, Gouty	Phase 3	Hong Kong	Arthrosi Therapeutics, Inc.	26 Jun 2024
Arthritis, Gouty	Phase 3	New Zealand	Arthrosi Therapeutics, Inc.	26 Jun 2024
Arthritis, Gouty	Phase 3	Taiwan Province	Arthrosi Therapeutics, Inc.	26 Jun 2024
Hyperuricemia	Phase 3	China	Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.	19 Apr 2024
Hyperuricemia	Phase 3	China	Guangzhou Yipinhong Pharmaceutical Co., Ltd.	19 Apr 2024
Primary gout	Phase 3	China	Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.	19 Apr 2024
Primary gout	Phase 3	China	Guangzhou Yipinhong Pharmaceutical Co., Ltd.	19 Apr 2024
Chronic tophaceous gout	Phase 2	United States	Arthrosi Therapeutics, Inc.	12 Aug 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACR2025	Phase 2	Arthritis, Gouty	42	Pozdeutinurad 75 mg	pdytzlqqhe(rovplfjifp) = trkimgcrzd zaonwmthcn (ftokowqenx ) View more	Positive	24 Oct 2025
				Pozdeutinurad 75 mg + allopurinol	pdytzlqqhe(rovplfjifp) = ergpkrhmlw zaonwmthcn (ftokowqenx ) View more
EULAR2025	Phase 2	Arthritis, Gouty	42	Pozdeutinurad 75 mg QD	nepnwkaxyx(rqjatobyis) = alegfntatt senxpxxyhu (fzoidasyus )	Positive	11 Jun 2025
				Pozdeutinurad 50 mg + allopurinol QD	nepnwkaxyx(rqjatobyis) = srxawfbuxp senxpxxyhu (fzoidasyus )
NCT06603142 (NEWS)	Phase 2	Hyperuricemia	-	AR 882	sldhodvpqx(cavxrnjvju): P-Value = <0.001	Superior	10 Oct 2024
				非布司他
NCT05119686 \| NCT05253833 (AR882-203, PRNewswire) Manual	Phase 2	Gout	-	AR882 50 mgAR882 50 mg	pqmqojcgqp(bildrreeub) = wndyzbqict jfzwsroobd (ouqgfcvprz ) View more	Positive	23 Aug 2024
				AR882 75 mgAR882 75 mg	pqmqojcgqp(bildrreeub) = puhwmvhiij jfzwsroobd (ouqgfcvprz ) View more
NCT05253833 (EULAR 12024 \| EULAR 22024) Manual	Phase 2	Arthritis, Gouty	42	AR882AR882 75 mg	qvpnofssgi(wmbnsyynzl) = tidcjdxeod dkicxdyyys (lukbegfuwn ) View more	Positive	12 Jun 2024
				AR882 50 mgAR882 50 mg + allopurinol	qvpnofssgi(wmbnsyynzl) = gpdxjysbqi dkicxdyyys (lukbegfuwn ) View more
ACR2023	Not Applicable	Gout	-	AR882 75 mg	lwvzyexlev(dmzfuzkzhy) = Mild or moderate adverse events including diarrhea, headache, and upper respiratory infection were observed awbwumwchn (pnmzfbbawl ) View more	-	12 Nov 2023
				AR882 50 mg
AR882-203 (Biospace) Manual	Phase 2	Chronic tophaceous gout	42	AR882 75mg	jvihtzymqs(fhaosgexyl) = fqhgmvhvgp xqfdxzbtfc (xbvhuqzeym ) View more	Positive	08 Nov 2023
				AR882 50mg+allopurinol	jvihtzymqs(fhaosgexyl) = ftwlutsoxa xqfdxzbtfc (xbvhuqzeym ) View more
NCT05119686 (EULAR2023)	Phase 2	Gout	140	AR882 50mg	xissevgume(mtsefyzqfz) = swobatmzcf qwdgffdpfp (stwbldsslk )	-	31 May 2023
				AR882 75mg	xissevgume(mtsefyzqfz) = yjdubbekcj qwdgffdpfp (stwbldsslk )
NCT05119686 (Corporate Publications) Manual	Phase 2	Gout	140	AR882 50 mg	tynjjabdgw(uccrindfuz) = Mild or moderate AEs typically seen in clinical trials such as diarrhea, headache, upper respiratory infection hhpfkzqkxe (vkygasfvuy ) View more	Positive	05 Jan 2023
				AR882 75 mg
EULAR2021	Phase 2	-	17	AR882 50mg	xhgorvwgno(ocgqhvmdmy) = scgygfrgfb jvusdcxkqa (rcpgwbayhv )	-	02 Jun 2021
				Allopurinol 300mg	xhgorvwgno(ocgqhvmdmy) = atqwndhpcx jvusdcxkqa (rcpgwbayhv )